Skip to main content
. 2022 Feb 13;62(3):705–712. doi: 10.47162/RJME.62.3.07

Figure 1.

Figure 1

E-cadherin immunoexpression (×400): (A) LRG–BCC, pT1; (B) HRG–BCC, pT1; (C) HGD–SCC, pT1; (D) LGD–SCC, pT1. BCC: Basal cell carcinoma; HGD: High grade of differentiation; HRG: High-risk grade; LGD: Low grade of differentiation; LRG: Low-risk grade; pT: Primary tumor; SCC: Squamous cell carcinoma